Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Radius Health (RDUS)

Radius Health (RDUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 542,096
  • Shares Outstanding, K 46,472
  • Annual Sales, $ 173,320 K
  • Annual Income, $ -132,990 K
  • 60-Month Beta 1.00
  • Price/Sales 3.23
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.24
  • Number of Estimates 5
  • High Estimate 0.13
  • Low Estimate -0.60
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +63.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.01 +6.45%
on 09/11/20
13.01 -9.92%
on 09/17/20
-0.28 (-2.37%)
since 08/21/20
3-Month
11.01 +6.45%
on 09/11/20
14.69 -20.19%
on 06/23/20
-2.66 (-18.50%)
since 06/22/20
52-Week
10.32 +13.57%
on 03/16/20
29.89 -60.79%
on 11/04/19
-16.75 (-58.83%)
since 09/20/19

Most Recent Stories

More News
Why Is Radius Health (RDUS) Down 7% Since Last Earnings Report?

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RDUS : 11.65 (-0.17%)
Radius Completes Enrollment in Phase III Osteoporosis Study

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

BPTH : 4.24 (-0.59%)
BLRX : 1.6543 (-2.11%)
RDUS : 11.65 (-0.17%)
CTLT : 85.09 (-0.54%)
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual...

RDUS : 11.65 (-0.17%)
Radius Health: Enrollment Completed for Phase 3 wearABLe trial

-- Innovative transdermal technology enables delivery of abaloparatide molecule - a peptide - across the skin

RDUS : 11.65 (-0.17%)
Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020.

RDUS : 11.65 (-0.17%)
Radius Health Provides Business Update

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS as well as the completion of enrollment for its Phase 3...

RDUS : 11.65 (-0.17%)
Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

LLY : 149.43 (-1.16%)
AMGN : 241.22 (-0.81%)
PCRX : 58.87 (-1.51%)
RDUS : 11.65 (-0.17%)
Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates

Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

RDUS : 11.65 (-0.17%)
Radius Health: 2Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Radius Health Inc. (RDUS) on Monday reported a loss of $43.9 million in its second quarter.

RDUS : 11.65 (-0.17%)
Sean Murphy joins Radius Health Board of Directors

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.

RDUS : 11.65 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RDUS with:

Business Summary

Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead product candidate, abaloparatide (BA058), is in development, in both...

See More

Key Turning Points

2nd Resistance Point 12.13
1st Resistance Point 11.90
Last Price 11.65
1st Support Level 11.42
2nd Support Level 11.17

See More

52-Week High 29.89
Fibonacci 61.8% 22.41
Fibonacci 50% 20.10
Fibonacci 38.2% 17.80
Last Price 11.65
52-Week Low 10.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar